Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus nivolumab in unresectable or metastatic hepatocellular carcinoma
NCT04310709Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, nivolumab in hepatocellular carcinoma (HCC), sponsored by Asan Medical Center. Started Jun 2020; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04310709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310709.